Status:
UNKNOWN
Seroprevalence of Pertussis Among Children and Adolescents in Croatia
Lead Sponsor:
University Hospital for Infectious Diseases, Croatia
Collaborating Sponsors:
Sanofi Pasteur, a Sanofi Company
Conditions:
Immunogenicity, Vaccine
Eligibility:
All Genders
6-18 years
Phase:
NA
Brief Summary
Pertussis is a vaccine preventable disease caused by Bordetella pertussis. Older children and adolescents with pertussis continue to be a significant source of infection for incompletely vaccinated in...
Eligibility Criteria
Inclusion
- children and adolescents from 6 to 18 years of age treated through Emergency room and/or Day hospital of Pediatric Infectious Diseases Department at UHID;
- appropriate vaccination with pertussis component containing vaccine by date and at the appropriate time, according to Croatian NIP proven by insight in the Vaccination Record Card
- written informed consent obtained from the subject's parent or caregiver, as well as from participants ≥ 16 years old.
Exclusion
- children under 6 years
- children and adolescents with acute respiratory symptoms
- children and adolescents with pertussis-like illness within 12 months
- children and adolescents with unknown, uncompleted or irregular vaccination record
- inpatients
- children and adolescents with immunodeficiencies
Key Trial Info
Start Date :
January 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 8 2022
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT04725669
Start Date
January 15 2021
End Date
September 8 2022
Last Update
February 15 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital for Infectious Diseases "Dr Fran Mihaljević"
Zagreb, Croatia, 10000